In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method
Autor: | Marco Cattaneo, Gian Marco Podda, Monica Bignotto, Mariangela Scavone, Eti Alessandra Femia, Sabrina Caberlon, Michele Dei Cas, J. Rizzo, Rita Paroni, Elena Bossi |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male 0301 basic medicine Metabolic Clearance Rate Science Administration Oral Absorption (skin) 030204 cardiovascular system & hematology Pharmacology Article 03 medical and health sciences Medical research 0302 clinical medicine Pharmacokinetics Tandem Mass Spectrometry Liquid chromatography–mass spectrometry In vivo Oral administration Thromboembolism medicine Humans Vascular diseases Chromatography High Pressure Liquid Whole blood Aspirin Multidisciplinary Chemistry Thrombosis Middle Aged Healthy Volunteers High-Throughput Screening Assays surgical procedures operative 030104 developmental biology Gastrointestinal Absorption Area Under Curve Pharmacodynamics Medicine Female Tablets Enteric-Coated Salicylic Acid medicine.drug |
Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) Scientific Reports |
ISSN: | 2045-2322 |
DOI: | 10.1038/s41598-021-89671-w |
Popis: | Low-dose aspirin (ASA) is used to prevent cardiovascular events. The most commonly used formulation is enteric-coated ASA (EC-ASA) that may be absorbed more slowly and less efficiently in some patients. To uncover these “non-responders” patients, the availability of proper analytical methods is pivotal in order to study the pharmacodynamics, the pharmacokinetics and the metabolic fate of ASA. We validated a high-throughput, isocratic reversed-phase, negative MRM, LC–MS/MS method useful for measuring circulating ASA and salicylic acid (SA) in blood and plasma. ASA-d4 and SA-d4 were used as internal standards. The method was applied to evaluate: (a) the "in vitro" ASA degradation by esterases in whole blood and plasma, as a function of time and concentration; (b) the "in vivo" kinetics of ASA and SA after 7 days of oral administration of EC-ASA or plain-ASA (100 mg) in healthy volunteers (three men and three women, 37–63 years). Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood. After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA. Higher between-subjects variability was seen after EC-ASA, and one subject had a delayed absorption over eight hours. Plasma AUC was 725.5 (89.8–1222) for EC-ASA, and 823.1(624–1196) ng h/mL (median, 25–75% CI) for plain ASA. After the weekly treatment, serum levels of TxB2 were very low (tmax. This method proved to be suitable for studies on aspirin responsiveness. |
Databáze: | OpenAIRE |
Externí odkaz: |